Your session is about to expire
← Back to Search
XmAb®808 + Pembrolizumab for Advanced Cancers
Study Summary
This trial will study the safety and effectiveness of using a drug combination to treat certain types of advanced cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My brain cancer is stable after treatment.I am fully active or restricted in physically strenuous activity but can do light work.My cancer is advanced, has spread, and didn't respond to standard treatments.I have never been treated with experimental drugs targeting CD28.My cancer is advanced, resistant to hormone therapy, and I haven't had PD1 therapy.My cancer can be measured by scans or has evaluable prostate cancer.You are expected to live for more than 3 months.You had a very serious health problem in the past caused by a previous immunotherapy treatment.You are currently getting treated with other cancer medications.
- Group 1: Dose Escalation and Expansion XmAb®808 administered in combination with pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any open slots for enrolment in this medical experiment?
"Affirmative. Information from clinicaltrials.gov supports the notion that this medical test is in search of participants, with its original posting taking place on November 1st 2022 and most recent update occurring on November 28th 2022. This trial requires 220 individuals to be recruited at 3 distinct medical centres."
How many individuals are being recruited for this medical research?
"Affirmative. Data found on clinicaltrials.gov confirms that this research, first made available to the public on November 1st 2022, is currently seeking participants. The researchers plan to enrol 220 patients from 3 sites in total."
What key goals is this clinical trial hoping to achieve?
"This experiment, which is expected to take 49 days to complete, will assess the prevalence of Treatment-Emergent Adverse Events (TEAEs). Secondary objectives include Cmax – peak plasma concentration levels; Progression-Free Survival as established by RECIST 1.1 assessment and PCWG3 for those with prostate cancer; and AUCtau - area under the curve in regards to plasma concentrations versus time."
How perilous are the effects of a Dose Escalation and Expansion XmAb808 combination treatment with pembrolizumab for patients?
"Power has assigned the safety of Dose Escalation and Expansion XmAb808 administered with pembrolizumab a score of 1 on account of it being an initial Phase 1 trial, which carries minimal evidence to support its efficacy or security."
Share this study with friends
Copy Link
Messenger